Eva Rohde – VJRegenMed

The potential of vesicular secretome fraction in hearing loss

admin_vjr_user — Thu, 26 Aug 2021 14:05:30 +0000

Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, describes ongoing research evaluating the therapeutic potential of the vesicular secretome fraction (VSF) in hearing loss. A single patient with Meniere’s disease, a condition of the inner ear, received a co-injection of VSF in one ear during surgical cochlear implantation, which resulted in a slight improvement in cochlear electrode function and no short- or long-term adverse events. The initiation of a Phase I safety clinical trial is pending, depending on the outcomes of ongoing pre-clinical safety testing, including biodistribution and toxicology assays. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

Promising avenues in extracellular vesicle-based therapeutics

admin_vjr_user — Tue, 24 Aug 2021 13:06:54 +0000

Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, provides an overview of the current landscape of research into extracellular vesicle (EV)-based therapeutics. She notes that in the last decade, the field has moved from basic, discovery research towards translation into the clinic, with a number of approaches currently being evaluated in clinical trials. Dr Rohde describes a number of EV-based therapeutic strategies under investigation, including the use of mesenchymal stromal cell (MSC)-derived EVs in neurodegenerative disorders, as well as the use of EVs in bone and tendon regeneration. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

Remaining barriers to the translation of EV-based therapies

admin_vjr_user — Tue, 24 Aug 2021 13:06:53 +0000

Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, considers some of the major bottlenecks that need to be addressed in order to drive the translation of extracellular vesicle-derived therapeutics to the clinic. She highlights the importance of collecting comparable preclinical data, the thorough preclinical characterization of EVs and secreted factors, as well an early focus on Chemistry, Manufacturing, and Control (CMC) processes. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.